Pharmaceutical Executive July 9, 2024
Jon Koch

Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.

Recently, more than 4,000 people from across the globe gathered in Atlanta to address the latest methodologies, data analytics, and evidence-based approaches that drive transformative change. The conference was held by ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR). One organization in attendance was Avalere Health, a global commercialization firm that partners with stakeholders across the healthcare ecosystem to provide a variety of services, including market access and HEOR. The following is Avalere Health’s global CEO’s perspective on...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Big Data, Conferences / Podcast, Patient / Consumer, Provider, Technology, Trends
Open AI And Thrive’s AI Health Coach Is A Bold Step Toward Hyper-personalized Healthcare
Proprioceptive Precision: Transforming Surgery Through AI and Human Expertise
The Shifting AI Landscape
The Synergy Of Humans And AI Is Reshaping The Workforce For The Future
Materialise Acquires Developer of AI Software for Cardiac Procedures

Share This Article